MedGenesis Therapeutix Inc.

MedGenesis Therapeutix Inc.

December 11, 2007 15:45 ET

MedGenesis Therapeutix Named One of Canada's Top 10 Life Science Companies

VICTORIA, BRITISH COLUMBIA--(Marketwire - Dec. 11, 2007) - MedGenesis Therapeutix Inc., a privately-held biopharmaceutical company, today announced that it has been recognized as one of Canada's Top 10 Life Sciences Companies for 2008. MedGenesis was chosen by a group of distinguished venture capital investors based on the Company's attractiveness as an exceptional investment in Canada.

"We are honoured to have received this award," said Chairman and Chief Executive Officer, Dr. Erich Mohr. "It recognizes the value and potential of our platform technology and the significant achievements made by our company in the last year."

Winners of the Canada's Top 10 Competition are chosen by an independent expert panel of Canadian and U.S. venture capitalists. Originally developed to promote the 10 most promising life science companies from across Canada to Canadian and international investors and partners, the competition has now expanded to showcase Canada's cleantech and technology sectors. Winning companies, working in partnership with OCRI, and the Canadian Consulates in Boston, New York City, San Diego and San Francisco, will participate in targeted investment forums in each city, providing them with an opportunity to meet with venture capital investors who have expressed an active interest in financing these companies.

About MedGenesis Therapeutix

MedGenesis Therapeutix Inc. is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life enhancing treatments to patients with serious Central Nervous System (CNS) Disease. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), with a groundbreaking CED platform for local drug delivery inside the brain. For more information please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For more information about the Canada's Top 10 Competition visit

Contact Information